Trials / Unknown
UnknownNCT03821363
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
Recombinant Humanized Anti- PD-1 Monoclonal Antibody（SCT-I10A） in Patients With Advanced Solid Tumors or Lymphoma :a Phase Ⅰ, Open-label, Multicenter Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 206 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma treated after failure of standard therapy.
Detailed description
This open label, multicenter phase I study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in advanced solid tumors or lymphoma treated with anti- PD-1 monoclonal antibody SCT-I10A. The trial will be divided into two parts: dose-exploration and indication expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCT-I10A | Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A） |
Timeline
- Start date
- 2018-12-13
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2019-01-29
- Last updated
- 2019-01-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03821363. Inclusion in this directory is not an endorsement.